How GLP-1 Drugs Became a Pre-Operative Variable in Plastic Surgery

GLP-1 drugs before surgery used to be a footnote on the intake form. They are now one of the first questions a careful practice asks. Semaglutide (sold as Ozempic and Wegovy) and the related dual-agonist tirzepatide (Mounjaro and Zepbound) moved through American medicine fast enough that surgical practice has had to adapt in real time. The drugs reached the operating room through two separate doors, and both of them changed the conversation that happens before a patient is sedated.

The question that interests us is not whether the drugs work for weight loss. That question is settled. It is what they changed about how a careful plastic surgeon plans an operation, and what a patient now has to disclose to be operated on safely.

The two doors the drugs came through

The first door is anesthesia. GLP-1 receptor agonists slow gastric emptying. That is part of how they work: food stays in the stomach longer, the patient feels full, and appetite falls. The same mechanism becomes a liability under sedation, where a stomach that is supposed to be empty may not be.

The second door is body contouring. A patient who loses forty, sixty, or a hundred pounds on these drugs is left with skin that does not retract to fit the smaller frame. Demand for arm lifts, thigh lifts, abdominoplasty, and lower body lifts has risen alongside the prescriptions. The drug that solved a weight problem created a skin problem, and the plastic surgeon is who the patient sees next.

Neither door is hypothetical. Both are now standing items in pre-operative planning.

Why anesthesiologists started asking about Ozempic

The short answer is aspiration risk. When a patient is sedated, the protective reflexes that keep stomach contents out of the airway are suppressed. The entire pre-operative fasting ritual (nothing to eat after midnight, clear liquids cut off hours before) exists to ensure the stomach is empty when those reflexes go offline. A drug that keeps the stomach full defeats the assumption that fasting alone makes the stomach safe.

In June 2023, the American Society of Anesthesiologists issued consensus guidance addressing exactly this. The recommendation was direct: hold daily-dosed GLP-1 agonists on the day of the procedure, and hold weekly-dosed agonists for one week before surgery. The guidance followed case reports of patients with residual gastric contents, and documented aspiration events, despite those patients having followed standard fasting instructions.

"

A drug that keeps the stomach full defeats the oldest assumption in surgical safety: that a fasting patient has an empty stomach.

"

The guidance got more careful, not less

The 2023 recommendation was a blunt instrument, and the field knew it. Holding a weekly medication for a full week is not trivial for a patient managing diabetes, and stopping abruptly carries its own consequences. In late 2024, a multi-society group (the American Society of Anesthesiologists alongside gastroenterology and metabolic surgery bodies) replaced the blanket hold with a risk-stratified approach.

The newer guidance asks the practical question instead of the categorical one: is this particular stomach empty? It points toward tools that answer it. Point-of-care gastric ultrasound can show residual contents directly. A clear-liquid diet for a day before the procedure reduces the volume of solids that might remain. The decision shifted from "stop the drug on a fixed schedule" to "confirm the stomach is safe before inducing anesthesia." That is a more honest standard, and a more demanding one.

What it changed about body contouring

The body contouring side of the story is slower and quieter, but it is reshaping practice just as much. Surgeons have a long-standing rule for post-weight-loss work: operate on a stable weight, not a moving one. The conventional window is several months of weight stability, often three to six, before contouring the result.

GLP-1 weight loss complicates that rule in two ways. The loss can be rapid, so the patient arrives wanting surgery while the weight is still falling. And patients on maintenance dosing may continue to lose slowly for longer than expected. A surgeon who removes excess skin from a body that is still shrinking is planning a second operation. The American Society of Plastic Surgeons has tracked rising demand for body contouring procedures through the period these drugs became widespread, and the better practices have responded by tightening, not loosening, the weight-stability conversation.

What a patient actually has to disclose

This is the part patients get wrong, and it is the part that matters most. The medication has to be disclosed by name, by dose, and by schedule, the same way you would disclose a blood thinner. Patients sometimes omit it because they think of it as a weight or diabetes drug rather than a surgical variable, or because they obtained it through a compounding pharmacy or a telehealth service and do not consider it part of their formal medical record.

That omission is dangerous. The anesthesiologist cannot manage a risk they do not know about, and the surgeon cannot time the procedure correctly without knowing the dosing schedule. The honest disclosure is simple: the drug, the dose, the date of the last injection, and whether you are still losing weight. Everything the surgical team needs to plan around the medication follows from those four facts.

The honest summary

GLP-1 drugs are now a standard pre-operative variable in plastic surgery, and they entered the field through two doors at once. On the anesthesia side, their effect on gastric emptying turned them into an aspiration-risk question, addressed first by a blunt 2023 hold recommendation and then by a more careful 2024 risk-stratified approach. On the body contouring side, rapid and sometimes continuing weight loss has made the old rule about operating on a stable weight more important, not less.

For a patient, the takeaway is unglamorous and entirely within your control: disclose the medication completely, and expect a surgeon worth choosing to ask about it before you do. The American Society of Anesthesiologists publishes the current peri-operative guidance, and the American Society of Plastic Surgeons publishes ongoing guidance on weight stability before body contouring. A practice that is current on both is a practice paying attention. A practice that treats a GLP-1 prescription as someone else's problem is not.